I also have more confidence in HGEN than in any other stock I have. And while I have a small number of shares not included in my open sell order, I'm not selling any of them yet. I'll watch what happens when we get into the price range estimated by the analysts to see if I want to sell those shares.
We have really seen Durrant's experience, that being of two dozen other products guided through validation, prove to be invaluable, most importantly, when it came to modifying endpoints and selecting "hospitalized and hypoxic" patients as the trial population. In addition, I think it was brilliant to continue with our internal trial, even though NIH picked up the trial cost for the BET trial. And also, making a deal with Kite/Gilead to use their resources, and a lot of their funding, in our collaborative trial...but refuse to sign an exclusivity agreement with them. That's chutzpah!
News 
Market Data 
Discover 
